

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

華康生物醫學控股有限公司

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 8622)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND APPOINTMENT OF MEMBERS OF THE BOARD COMMITTEES

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Huakang Biomedical Holdings Company Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) is pleased to announce that Ms. Wang Yachun (“**Ms. Wang**”) has been appointed as an independent non-executive director of the Company (“**INED**”) and a member of each of the audit committee, remuneration committee (“**Remuneration Committee**”) and nomination committee of the Company with effect from 30 June 2025.

Ms. Wang, aged 41, has experience in accounting. Ms. Wang is currently serving as a director of Jiangsu Zhengzhe Financial Management Consulting Co., Ltd.* (江蘇正哲財務管理諮詢有限公司), a company engaged in providing the financial management consulting and business management consulting to corporations in the People’s Republic of China (the “**PRC**”).

Ms. Wang obtained a degree of Bachelor of Accounting from Hunan Agricultural University (湖南農業大學) in the PRC in 2008. She has passed all required subjects of the professional stage of the National Uniform Certified Public Accountant Examination of the PRC in 2014.

Ms. Wang has entered into an appointment letter with the Company for an initial term of three years commencing from 30 June 2025 and will continue thereafter until terminated by either party serving not less than one month’s written notice to the other party. Pursuant to the appointment letter, Ms. Wang is entitled to a director’s emolument of HK\$120,000 per annum. Such fee is determined by the Board based on the recommendation of the Remuneration Committee of the Company with reference to her experience, responsibilities, workload and time devoted to the Company and will be subject to review by the Remuneration Committee of the Company from time to time. Save as disclosed above, Ms. Wang is not expected to receive any other remuneration for holding her office as an INED.

In accordance with the articles of association of the Company, Ms. Wang will hold office until the next following annual general meeting of the Company and shall then be eligible for re-election. Ms. Wang will be subject to rotation requirements as contained in the articles of association of the Company and shall retire from office by rotation at least once every three years.

Ms. Wang confirmed that (i) she meets the independence criteria as set out in Rule 5.09 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (“**GEM Listing Rules**”); (ii) she has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the GEM Listing Rules) of the Company; and (iii) there are no other factors that may affect her independence at the time of her appointment.

* For identification purpose only

Save as disclosed above, as at the date of this announcement, Ms. Wang (i) does not hold any other position in the Company and other members of the Group; (ii) did not hold any other directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not possess any other major appointments or professional qualifications; (iv) does not have any relationship with any other Directors, senior management or substantial or controlling shareholders of the Company; and (v) does not have any interests in the shares of the Company or any of its associated corporations which is required to be disclosed under Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, the Board is not aware of any information which is disclosable nor is/was Ms. Wang involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 17.50(2)(h) to (v) of the GEM Listing Rules and there are no other matters concerning Ms. Wang that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its warmest welcome to Ms. Wang for joining the Board.

By Order of the Board
Huakang Biomedical Holdings Company Limited
Zhang Shuguang
Chairman and Executive Director

Hong Kong, 30 June 2025

As at the date of this announcement, the Executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Ms. Zhang Yujing; the non-executive Directors are Dr. Bu Su and Dr. Xu Ming; and the independent non-executive directors are Dr. Chow Kwok Fai Joseph, Ms. Wang Yachun, Dr. Cheng Faat Ting Gary and Mr. Tsui Wing Tak.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcements" page of the Stock Exchange website at www.hkexnews.hk for at least seven days from the date of publication and on the Company's website at www.huakangbiomedical.com.